Penn State Hershey and Serametrix to Seek Companion Diagnostic for Immunotherapy in Pediatric Cancers

SAN DIEGO--(BUSINESS WIRE)--Penn State Hershey Children’s Hospital and Serametrix will collaborate on developing a diagnostic test for predicting individual clinical response to a novel immune therapy for brain cancer, it was announced today. The serum-based test is designed to determine patient immune responses from cancer immunotherapy, enabling clinicians to determine in the future which patients may be more likely to respond to this treatment regimen.